Sacituzumab govitecan and tumor microenvironment shifts in metastatic triple-negative breast cancer

Sacituzumab govitecan treatment correlates with an immunosuppressive shift in mTNBC

INDICATION
Breast
BIOMARKER
CXCL/SPP1 (CS)

Violin plots compare gene expression changes with Sacituzumab Govitecan (p=0.047) and Chemotherapy (p=0.41).

 

Figure 1. log(CXCL9/SPP1) values comparison between pre- and post-treated patients with TNBC treated with (A) Sacituzumab Govitecan, and (B) Chemotherapy. Wilcoxon rank sum test p-values are depicted.

Related cases

Icon with three vertical bars and a circle, resembling a bar graph or LinkedIn logo.Lens Library
A blue grid with dark blue squares forming a descending diagonal path, possibly a heatmap.

Optimizing therapy sequencing for HR+ HER2- metastatic breast cancer

2026-05-26
Breast
HER2
Icon with three vertical bars and a circle, resembling a bar graph or LinkedIn logo.Lens Library
Unable to determine image content.

ESR1 mutations and copy number loss in breast cancer

2026-05-26
Breast
ESR1
Icon with three vertical bars and a circle, resembling a bar graph or LinkedIn logo.Lens Library
Abstract pixelated pattern featuring a grid with diagonal lines of blue, green, purple, and black dots.

NF1 and MKI67 expression as prognostic biomarkers in ER+ metastatic breast cancer

2026-05-26
Breast
MKI67
NF1